1. Home
  2. BWIV vs NRXP Comparison

BWIV vs NRXP Comparison

Compare BWIV & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BWIV

Blue Water Acquisition Corp. IV Class A Ordinary Shares

N/A

Current Price

$9.96

Market Cap

176.0M

Sector

Finance

ML Signal

N/A

Logo NRX Pharmaceuticals Inc.

NRXP

NRX Pharmaceuticals Inc.

HOLD

Current Price

$3.22

Market Cap

151.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWIV
NRXP
Founded
N/A
2015
Country
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.0M
151.1M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
BWIV
NRXP
Price
$9.96
$3.22
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$38.25
AVG Volume (30 Days)
44.7K
606.6K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.70
EPS
N/A
N/A
Revenue
N/A
$1,225,000.00
Revenue This Year
N/A
$2,547.84
Revenue Next Year
N/A
$1,591.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.89
$1.65
52 Week High
$10.00
$5.06

Technical Indicators

Market Signals
Indicator
BWIV
NRXP
Relative Strength Index (RSI) 52.38 40.81
Support Level $9.90 $3.12
Resistance Level $10.00 $3.62
Average True Range (ATR) 0.01 0.14
MACD 0.00 -0.01
Stochastic Oscillator 55.56 21.35

Price Performance

Historical Comparison
BWIV
NRXP

About BWIV Blue Water Acquisition Corp. IV Class A Ordinary Shares

Blue Water Acquisition Corp IV is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: